Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)

Joon-Young Song; Chih-Jen Chang; Charles Andrews; Javier Diez-Domingo; Myoung-don Oh; Ron Dagan; Jonathan Hartzel; Alison Pedley; Jianing Li; Tina Sterling; Gretchen Tamms; Joseph A. Chiarappa; Jeannine Lutkiewicz; Luwy Musey; Yingmei Tu; Ulrike K. Buchwald

doi:10.1016/j.vaccine.2021.08.038

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)

Vaccine ◽

10.1016/j.vaccine.2021.08.038 ◽

2021 ◽

Vol 39 (43) ◽

pp. 6422-6436

Author(s):

Joon-Young Song ◽

Chih-Jen Chang ◽

Charles Andrews ◽

Javier Diez-Domingo ◽

Myoung-don Oh ◽

...

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Healthy Adults ◽

Phase Iii ◽

Phase Iii Trial

Download Full-text

Immunogenicity and safety of fully liquid DTaP5-IPV-Hib compared with DTaP3-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: A phase III, single-blind, randomised, controlled, multicentre study

Vaccine ◽

10.1016/j.vaccine.2011.07.078 ◽

2011 ◽

Vol 29 (43) ◽

pp. 7370-7378 ◽

Cited By ~ 9

Author(s):

Emmanuel Grimprel ◽

Jacek Wysocki ◽

Florence Boisnard ◽

Stéphane Thomas ◽

Grace Mwawasi ◽

...

Keyword(s):

Multicentre Study ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Phase Iii ◽

Randomised Controlled ◽

Heptavalent Pneumococcal Conjugate Vaccine ◽

Single Blind

Download Full-text

Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults

Vaccine ◽

10.1016/j.vaccine.2015.04.025 ◽

2015 ◽

Vol 33 (24) ◽

pp. 2793-2799 ◽

Cited By ~ 36

Author(s):

Richard McFetridge ◽

Ajoke Sobanjo-ter Meulen ◽

Steven D. Folkerth ◽

John A. Hoekstra ◽

Michael Dallas ◽

...

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Healthy Adults

Download Full-text

Carriage ofStreptoccoccus pneumoniaein healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children

Human Vaccines & Immunotherapeutics ◽

10.4161/hv.23253 ◽

2013 ◽

Vol 9 (3) ◽

pp. 614-620 ◽

Cited By ~ 17

Author(s):

Filippo Ansaldi ◽

Daniela de Florentiis ◽

Paola Canepa ◽

Antonella Ceravolo ◽

Emanuela Rappazzo ◽

...

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Vaccine Coverage ◽

Healthy Adults ◽

Very High

Download Full-text

Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study

Vaccine ◽

10.1016/j.vaccine.2018.02.013 ◽

2018 ◽

Vol 36 (14) ◽

pp. 1908-1916 ◽

Cited By ~ 8

Author(s):

Clare L. Cutland ◽

Terry Nolan ◽

Scott A. Halperin ◽

Zafer Kurugol ◽

Khatija Ahmed ◽

...

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Phase Iii ◽

Meningococcal Vaccine ◽

Open Label ◽

Randomised Study ◽

Quadrivalent Meningococcal Vaccine

Download Full-text

Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)

Vaccine ◽

10.1016/j.vaccine.2021.12.067 ◽

2022 ◽

Author(s):

Jakub K. Simon ◽

Nina Breinholt Staerke ◽

Maria Hemming-Harlo ◽

Stacey Layle ◽

Ron Dagan ◽

...

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Healthy Adults ◽

Phase 3

Download Full-text

A phase III randomised, open label clinical trial evaluating the immunogenicity of a 10-valent pneumococcal conjugate vaccine booster compared to the standard 13-valent pneumococcal conjugate vaccine booster given at 12 months of age to healthy children who have received the 13-valent pneumococcal conjugate vaccine at 2 and 4 months of age

http://isrctn.org/> ◽

10.1186/isrctn57878347 ◽

2012 ◽

Author(s):

Faye Alexander

Keyword(s):

Clinical Trial ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Phase Iii ◽

Healthy Children ◽

Open Label ◽

Vaccine Booster

Download Full-text

Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial

Expert Review of Vaccines ◽

10.1080/14760584.2017.1321990 ◽

2017 ◽

Vol 16 (6) ◽

pp. 641-656 ◽

Cited By ~ 5

Author(s):

Shabir A Madhi ◽

Anthonet Koen ◽

Lisa Jose ◽

Marta Moreira ◽

Nadia van Niekerk ◽

...

Keyword(s):

South Africa ◽

Haemophilus Influenzae ◽

Conjugate Vaccine ◽

Phase Iii ◽

Phase Iii Trial

Download Full-text

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

Human Vaccines & Immunotherapeutics ◽

10.1080/21645515.2021.1890511 ◽

2021 ◽

pp. 1-9

Author(s):

Brandon Essink ◽

James Peterson ◽

Kari Yacisin ◽

Himal Lal ◽

Sarah Mirza ◽

...

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Phase 1 ◽

Healthy Adults

Download Full-text

The data management of a phase III efficacy trial of an 11-valent pneumococcal conjugate vaccine and related satellite studies conducted in the Philippines

BMC Research Notes ◽

10.1186/1756-0500-5-274 ◽

2012 ◽

Vol 5 (1) ◽

pp. 274 ◽

Cited By ~ 1

Author(s):

Diozele Hazel M Sanvictores ◽

Marilla G Lucero ◽

Hanna Nohynek ◽

Veronica L Tallo ◽

Antti Tanskanen ◽

...

Keyword(s):

Data Management ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

The Philippines ◽

Phase Iii ◽

Efficacy Trial

Download Full-text

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults

Vaccine ◽

10.1016/j.vaccine.2007.06.004 ◽

2007 ◽

Vol 25 (33) ◽

pp. 6164-6166 ◽

Cited By ~ 78

Author(s):

Daniel A. Scott ◽

Steven F. Komjathy ◽

Branda T. Hu ◽

Sherryl Baker ◽

Lois A. Supan ◽

...

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Phase 1 ◽

Healthy Adults ◽

Phase 1 Trial

Download Full-text

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)

Immunogenicity and safety of fully liquid DTaP5-IPV-Hib compared with DTaP3-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: A phase III, single-blind, randomised, controlled, multicentre study

Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults

Carriage ofStreptoccoccus pneumoniaein healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children

Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study

Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)

Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

The data management of a phase III efficacy trial of an 11-valent pneumococcal conjugate vaccine and related satellite studies conducted in the Philippines

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)